During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US, about the results of the P-2001 study.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?
P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?
Sekeres reports the promising results from the high-risk MDS cohort (n = 67) of the P-2001 study, evaluating efficacy and safety of pevonedistat plus azacitidine versus azacitidine alone.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox